Matthew Ros, See Remarks at Epizyme, Inc. (EPZM), sold 2,728 shares at $16.15 ($44K) on 2020-06-26, disclosed to the SEC on 2020-06-30.
Scheduled sale ($44k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| EPZM | SELL | 2020-06-22 | $4.7M | — | Filing → |
| EPZM | SELL | 2020-03-26 | $19K | — | Filing → |
| EPZM | SELL | 2020-01-27 | $46K | — | Filing → |